Amgen to Acquire Dark Blue Therapeutics for up to $840 Million
Strengthening Early-Stage AML Drug Discovery and Targeted Protein Degradation Capabilities
Amgen has announced an agreement to acquire Dark Blue Therapeutics for up to $840 million, reinforcing its strategy to accelerate research and development in acute myeloid leukemia (AML). The transaction includes an upfront payment and development-based milestone payments, subject to customary closing conditions.
The acquisition highlights Amgen’s continued focus on early-stage oncology programs with clearly defined mechanisms of action, reflecting a willingness to invest ahead of clinical development when scientific differentiation is strong.
Acquired Assets and Scientific Rationale
Dark Blue Therapeutics’ lead asset is a small-molecule targeted protein degrader designed to address specific molecular subtypes of AML. The program targets MLLT1 and MLLT3, two proteins known to play a key role in driving disease biology in selected patient populations.
Although the program remains at the preclinical stage, reports indicate promising anti-leukemic activity through a mechanism distinct from existing therapies. The development strategy is designed to support both monotherapy and combination approaches, with the aim of improving treatment durability and overcoming resistance.
Strategic Fit and Industry Context
The transaction aligns with Amgen’s broader oncology strategy, which emphasizes deep disease biology, mechanism-driven discovery, and early integration of innovative platforms into its internal R&D organization.
Following completion of the acquisition, Dark Blue Therapeutics’ programs will be fully integrated into Amgen’s research infrastructure and advanced toward clinical development. The deal also expands Amgen’s capabilities in targeted protein degradation, a modality that continues to gain momentum across oncology drug discovery.
Industry Implications
Rather than targeting late-stage or near-commercial assets, this acquisition underscores a broader industry shift toward early, differentiated programs with long-term development potential. Competition for preclinical oncology assets with clear molecular rationale remains strong, particularly in areas of high unmet medical need such as AML.
Amgen and Dark Blue Therapeutics are to be congratulated on this strategic milestone, and the program’s progression toward the clinic will be closely watched.